ADVANCED VIRAL RESEARCH CORP
10-Q, EX-27, 2000-08-14
PHARMACEUTICAL PREPARATIONS
Previous: ADVANCED VIRAL RESEARCH CORP, 10-Q, 2000-08-14
Next: BUTLER INTERNATIONAL INC /MD/, 10-Q, 2000-08-14



<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AND CONSOLIDATED STATEMENT OF OPERATIONS OF ADVANCED
VIRAL RESEARCH CORP. FOR THE SIX MONTHS ENDED JUNE 30, 2000 AND IS QUALIFIED IN
ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                                               6-MOS
<FISCAL-YEAR-END>                                     DEC-31-1999
<PERIOD-START>                                        JAN-01-2000
<PERIOD-END>                                          JUN-30-2000
<CASH>                                                  2,571,008
<SECURITIES>                                                    0
<RECEIVABLES>                                                   0
<ALLOWANCES>                                                    0
<INVENTORY>                                                19,729
<CURRENT-ASSETS>                                        2,710,391
<PP&E>                                                  1,704,922
<DEPRECIATION>                                                  0
<TOTAL-ASSETS>                                          5,009,675
<CURRENT-LIABILITIES>                                     620,088
<BONDS>                                                         0
                                           0
                                                     0
<COMMON>                                                    3,608
<OTHER-SE>                                                      0
<TOTAL-LIABILITY-AND-EQUITY>                            5,009,675
<SALES>                                                     4,961
<TOTAL-REVENUES>                                            4,961
<CGS>                                                           0
<TOTAL-COSTS>                                                   0
<OTHER-EXPENSES>                                        2,792,896
<LOSS-PROVISION>                                                0
<INTEREST-EXPENSE>                                        677,504
<INCOME-PRETAX>                                       (3,390,848)
<INCOME-TAX>                                                    0
<INCOME-CONTINUING>                                             0
<DISCONTINUED>                                                  0
<EXTRAORDINARY>                                                 0
<CHANGES>                                                       0
<NET-INCOME>                                          (3,390,848)
<EPS-BASIC>                                                (0.00)
<EPS-DILUTED>                                              (0.00)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission